• Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
  • Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
  • Addex Rises on Positive Rodent Experiment Results: Zurich Mover
  • Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
  • Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
  • Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
  • U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
  • Largest Weekly Option Sentiment Changes for S&P 500 Companies
  • SAC Digs In as Deadline Nears for U.S. Insider Cases
  • Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
  • Puma Biotech Gains After Rival Drug Data Show No Threat
  • Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
  • Billionaire Frost Props Up Prolor Bid With Stock Buys
  • U.S. Stock Options With Biggest Changes in Implied Volatility
  • Gene-Testing Dispute Focuses on How Much a Patient Should Know
« Previous 1 2 Next »